Commercializing Quick, Inexpensive Genetic Testing For The Early

Detection Of Diseases January 2017

CNA DIAGNOSTICS INC.

Disclaimer

2

This Presentation is based upon information supplied by CNADiagnostics Inc. (“CNADx” or the "Company") solely for use byprospective strategic partners and/or investors in the company. ThisPresentation does not purport to be all-inclusive or to contain all of theinformation that a prospective strategic partner and/or investor maydesire. No representation or warranty is made as to the accuracy orcompleteness of any of the information contained herein. Eachrecipient of this memorandum agrees that all of the informationcontained herein is of a confidential nature, that he will treat it in aconfidential manner, and that he will not directly or indirectly, disclose,or permit his agents or affiliates to disclose, any of such informationwithout the prior written consent of the Company. Neither thisPresentation, nor its delivery to any prospective strategic partner and/orinvestor, shall constitute an offer to sell or the solicitation of an offer tobuy any securities of the Company, nor shall this Presentation beconstrued to indicate that there has been no change in the affairs of theCompany. This Presentation contains "forward-looking information",which is disclosure regarding possible events, conditions or financialperformance that is based on assumptions about future economicconditions and courses of action. In particular, the forward-lookinginformation in this presentation includes: statements regarding timing

and outcomes of research, development, and commercializationactivities, financing activities, protection of intellectual property,market share and growth. Actual results may vary from the forward-looking information in this presentation. Material risk factors that couldcause actual results to differ materially from the forward-lookinginformation include: (i) CNADx’s ability to develop commercially viableproducts; (ii) CNADx’s ability to achieve profitability; (iii) CNADx’s abilityto produce and market its products; (iv) CNADx’s ability to obtainregulatory approval of its products; (v) CNADx’s ability to protect itsintellectual property; (vi) competitive and alternative technologies; and(vii) CNADx’s ability to obtain financing to support its operations. Thematerial factors or assumptions that were used to develop the forward-looking information in this presentation include: our ability to achieveresearch and development objectives, timing of proposedcommercialization plans, ability to protect intellectual property, abilityto secure needed financing or our ability to develop sufficient marginsin the business through development of proposed technology or othermeans. CNADx's views regarding possible events, conditions or financialperformance may change. However, CNADx does not intend to updatethe forward-looking information in this presentation, except as requiredby applicable securities legislation.

Company OverviewCNA Diagnostics Inc. (CNADx) is a molecular diagnostics company implementing a diagnostic platform capable of detecting multiple human and animal diseases at a very early stage, most beneficially, long before clinical signs can provide evidence a disease or infection even exists.

3

DNA

Nucleic Acid

ThymineGuanine

Adenine

Cytosine

Deoxyribose

Company Highlights

Proprietary technology that identifies chronic disease at the earliest stages for livestock, companion animals and humans before clinical signs.

Lead order for a minimum one million bovine tests at $12 USD per test, high gross margins, subject to initial commercialization (Q4/17 ).

Distribution planned through license agreements with well known major industry participants.

Multi-disease testing platform significantly improves food safety for consumers and the profitability for the livestock industry.

High barriers to entry, long term expansion opportunity, seasoned leadership and a comprehensive product portfolio.

Multibillion dollar market opportunity.

6

Intellectual Property

7

CNADx owns IP Process of Identifying proprietary CNA sequences expressed by an animal with a particular disease. Assigned from University of Calgary.

Multiple patents being explored to build IP portfolio.

Each test qualifies for its own proprietary patent application building a pipeline of value added intellectual property.

Provisional U.S. patent applications.

Followed by PCT patent applications covering a minimum of 30 countries that show high propensity to cattle diseases.

National patent applications in the major feedlot and dairy production regions will include U.S., Canada, European Union, China, Brazil, Mexico, Australia and South Africa.

Technology – CNADx Biomarkers

8

Intellectual property developed at the University of Calgary over a seven year period.

Identified genetic biomarkers linked to specific human and animal diseases, and implemented in a diagnostic platform that distinguishes those biomarkers and as a result detects chronic disease at the earliest stages.

Invented by Dr. Robert Church, Professor Emeritus of Medical Biochemistry and Molecular Biology, University of Calgary; and University Professor Dr. Christoph Sensen and his team at the University of Calgary and the Graz University of Technology, Institute of Molecular Biotechnology in Austria.

Acquired by CNADx in 2015.

Proof of concept completed, nearing commercialization with completion of final sequencing.

9

One in every 1000 vesicles in the blood contains DNA that can be used for marker development

Biomarkers - The Messengers Of Disease

Exosomes are nano sized vesicles naturally produced by many varying cell types

Stress of disease and death to cells releases exosomes

into the bloodstream

Exosomes are loaded with nucleic acid cargo representing

the homeostatic state of the producing cell

DNA Sequencing & BioinformaticsIS NOT NEW TECHNOLOGY

10

Sequencing is a Readily Available Service

Seven years to develop bioinformatics pipeline allowing CNADxBiomarkers to determine the “early detection of disease” in the bloodbefore clinical signs are present.

OUR DIFFERENCE

NEXT GENERATION SEQUENCING OF DNA

In-House Bioinformatics System for Mapping DNA

PROPRIETARY BIOINFORMATICS COMPUTING TECHNOLOGY

Diagnostic Testing Devices

11

The power of DNA testing in the palm of your hand

QuantuMDX – Q.POC Spartan - CubeFraunhofer Gesellschaft

Portable Testing DeviceInternal Diagnostic

Hardware Development

Developing hardware to support our global diagnostics markets

Medium-High Capacity Testing Low-Medium Capacity TestingHigh Capacity Testing

Early detection of disease to better manage treatment and cure.

Reduces production costs to producers by targeting treatments.

Reduces excessive use and misuse of antibiotics.

Increases and secures trade in global livestock market.

Improves livestock industry’s ability to address food safety concerns.

Improves measurement of efficacy for new drug and vaccine development.

Reduces environmental impact of overuse of antibiotics.

Limits antimicrobial resistance, and reduces costs.

12

CNADx Providing A Solution To The Livestock Industry

Commercialization

• The company is pursuing the quickest path to commercialization.

• Bovine genetic biomarker tests for the early detection of Bovine Respiratory Disease, Johne's Disease and Bovine Spongiform Encephalopathy (BSE).

• Significantly improves food safety for consumers and the profitability for the livestock industry.

• Purchase order in hand for min one million tests at $12 USD per test.

• Anticipated launch Q4 2017.

13

DNA

Nucleic Acid

ThymineGuanine

Adenine

Cytosine

Deoxyribose

Feedlot Health Management Services (FHMS)

Minimum standing order for one million BRDtests/year for their clients beef cattle feedingoperations in Canada & USA.

FHMS have projected up to 3 million tests/year usage.

$12USD per test.

Canada/US combined BRD market is 5x larger at 15million tests per year – testing only the cattle at highrisk of developing the disease.

Lead Commercial Deal

14

Market Collaborations Alta AgriCorp China – Asia Pacific – Livestock - All

European Pharma Laboratory – EU, Russia – Livestock - All

Veterinary Health Group – USA – Companion Animals

Merck Animal Health - TBD

FHMS – Canada and USA – Livestock – Feeder Cattle

QuantuMDX – diagnostic hardware

Spartan Bioscience – diagnostic hardware

Fraunhofer Gesellschaft – diagnostic hardware

Government of Canada – Department of Defense – Human Sepsis

A biomarker analysis platformthat can detect disease in bothanimals and humans.

Blood sample analysis will simultaneously screen for multiple diseases from single samples.

Detects disease at earliest stages long before clinical symptoms are recognized.

Target Biomarkers for the Beef and Dairy Industry

Multi-Disease Testing Opportunity

Bovine

Brucellosis

Bovine

Tuberculosis

Johne’s

Disease

Bovine

Leukosis

Foot &

Mouth

Disease

BSE

“Mad Cow”

Disease

Bovine

Respiratory

Disease

Bovine

Mastitis

ANIMALS CATTLE SWINE COMPANION EQUINE SHEEP

DISEASES 14 7 10 11 11

The chart above identifies only the major chronic diseases that affect livestock animals globally establishing the testing development pipeline for CNA Diagnostics Inc. (Figures by the OIE - World Organization for Animal Health)

Overall Livestock Opportunity

17

Industry Benefits DevelopmentLivestock producers can make more

informed decisions regarding animal health and disease

management and ensure the production of safe, abundant and

high-quality animal protein.

Work with industry partners to develop and market proprietary

molecular diagnostic technologies with the potential to increase

overall herd health & productivity.

Cancers

Severe

Trauma

AutoImmune

Disease

Chronic

Inflammatory

Diseases

Cardiovascular

Disease

Acute

Inflammatory

Conditions

Infectious

Diseases

Degenerative

Diseases

Respiratory

Diseases

Degenerative

Diseases

Enteric

Diseases

Infectious

Diseases

Current Diagnostic Biomarker Targets

18

BRD – Bovine Respiratory Disease

SepsisJohne’s Disease

Anemia

Gross Market Potential figures are used to establish exclusive territorial licence fees. Risk of Disease are numbers derived from averaging morbidityrates that develop within beef and dairy cattle industry. Source FDA –Animal & Veterinary

Market Opportunity

19

MARKET Beef CattlePopulation (MM)

Dairy CattlePopulation (MM)

Beef CattleRisk of Disease (MM)

Dairy CattleRisk of Disease (MM)

Gross MarketPotential (Annual)

China 48.2 15.6 14.0 4.5 $277,500,000

Brazil 38.7 39.3 11.2 11.4 $339,000,000

India 38.5 127.0 11.2 36.8 $720,000,000

USA 30.5 9.3 8.9 2.7 $174,000,000

EU 26.8 23.6 7.8 6.8 $219,000,000

Argentina 12.1 2.0 3.5 0.6 $61,500,000

Australia 8.1 1.7 2.4 0.5 $43,500,000

Russia 6.7 8.0 1.9 2.3 $63,000,000

Mexico 5.9 3.3 1.7 1.0 $40,500,000

Columbia 4.2 1.5 1.2 0.4 $24,000,000

New Zealand 4.4 5.0 1.3 1.5 $42,000,000

Canada 3.0 1.0 0.9 0.3 $18,000,000

Ukraine 2.2 2.2 0.6 0.6 $18,000,000

Uruguay 2.3 0.4 0.7 0.1 $12,000,000

Venezuela 0.8 1.3 0.2 0.4 $9,000,000

Egypt 1.7 4.2 0.5 1.2 $25,500,000

Japan 1.1 0.7 0.3 0.2 $7,500,000

South Africa 3.1 1.2 0.9 0.4 $19,500,000

South Korea 1.0 0.3 0.3 0.1 $6,000,000

Totals 239.3 247.6 69.5 71.8 $2,119,500,000

Timeline & Milestones

20

Current Q1/17 Q2/17 Q3/17 Q4/17 Q1/18

Phase 1

BRD - Cattle Sequencing Marker ID IP Licensing

Johne’s Disease - Cattle Sequencing Marker ID IP Licensing

Sepsis Bacterial (Phase 2) - Human New Samples Sequencing Marker ID IP Licensing

Phase 2

Anemia (Companion Animals) Samples Sequencing Marker ID IP

Sepsis Fungal - Human Samples Sequencing Marker ID IP

Phase 3

Breast Cancer - Human Discovery Samples Sequencing Marker ID

Preeclampsia - Human Discovery Samples Sequencing Marker ID

Bovine Leukosis - Cattle Discovery Samples Sequencing Marker ID

Recent Industry Consolidation

GHO Capital acquires DNA Diagnostics for €104 million / $152 million CAD.

DNA profiling company testing animals for potential disease candidates.

Merck buys 93% of Brazil animal health company Vallée for $400 million.

Boehringer Ingelheim buys Merial Animal Health, a division of Sanofi for €11.4 bn / $16.7 bn CAD.

Mars Inc. agrees to buy the animal hospital chain VCA Inc. for $7.7 billion making a bigger bet on a booming industry: pet care.

M&A spending in animal health was $12.2 bn in 2015

compared with $6.2 bn in 2014 and $1.1 bn in 2013.

22

Corporate Structure

9.0M common shares @ $0.30

3.3M options and warrants @ ~$0.30

Implied Market Cap Fully Diluted - $3.7M

Cash Investment $ 542k

23

Use of Proceeds

25

Phase 1 (Now – Q2 2017)

Completion of BRD Sequencing & Biomarker Development $450,000

Completion of Johne’s Sequencing & Biomarker Development $450,000

G&A / IP Legal $250,000

Total Requirements $1,150,000

Phase 2 (Q2 2017 – Q4 2017)

Sample Extraction and Amplification for Anemia in Dogs $140,000

Anemia Sequencing & Biomarker Development $500,000

G&A / IP Legal $350,000

Total Requirements $990,000

Phase 2 is a repeatable process for hundreds of human and animal diseases. 6 months is the average time from first samples extracted to IP lock up. Roughly $1M average to prepare a disease for licensing.

Board and Management

26

A veterinarian active in Canada’s cattle industry with extensive international experience. Dr. Chalack currently holds the position of international sales manager with Alta Genetics Inc. based in Balzac, Alberta, and is owner/partner and president of Rocky Mountain Holsteins Ltd.

Dr. Chalack serves as the chairman of the board of Alberta Livestock and Meat Agency (ALMA); a board member of Alberta Energy Regulator, and is a past chairman of the board for the Calgary Exhibition and Stampede. He chairs the ministerial advisory board of the Canadian Food Inspection Agency (CFIA) and is a director for Horse Racing Alberta and a member of the Dean’s Advisory Council for the new University of Calgary Faculty of Veterinary Medicine.

Dr. Chalack is a member of the Canadian Institute of Corporate Directors and has recently been appointed to the board of the Canadian Dairy Network (CDN).

In addition to his 25 years with Alta Genetics Inc., Dr. Chalack practiced veterinary medicine as a partner at Moore & Co. Veterinary Clinic, with a focus on large animal medicine, bovine health, and reproduction management. Dr. Chalack has adopted the One Health Initiative in his work, which is a worldwide strategy for collaboration in advancing the health of humans, animals, and the environment to encourage sustainability.

Dr. Chalack holds a Doctorate of Veterinary Medicine from the University of Saskatchewan and attended the University of Alberta’s Faculty of Agriculture. As recognition for many years spent advancing Canadian agriculture domestically and internationally, Dr. Chalack was inducted into the Canadian Agricultural Hall of Fame in 2011.

Dr. David Chalack

Director

Dr. G. Kee Jim

Director

Dr. Jim received his Doctor of Veterinary Medicine (D.V.M.) in 1983 from the Western College of Veterinary Medicine, Saskatoon, Saskatchewan. He is the founding partner of Feedlot Health Management Services Ltd. (FHMS), and the 2008 recipient of the American Association of Bovine Practitioner’s Practitioner of the Year award. Dr. Jim is also a past recipient of the American Association of Bovine Practitioner’s Beef Award for Excellence in Veterinary Preventative Medicine, the Schering-Plough Animal Health Veterinary Award from the Canadian Veterinary Medical Association, and the Canadian Animal Health Institute Leadership Award. Dr. Jim is currently the CEO and Managing Director of Feedlot Health Management Services Ltd.

Kee Jim’s companies, G.K Jim Farms and affiliated companies Cattlinc Inc, Silverado Cattle Inc., Taweel Cattle Company Ltd., Korova Feeders Ltd., and Diamond Feeders are major players in the Canadian and United States cattle industries through ownership of cows, backgrounding cattle, grass cattle and feedlot cattle. In addition, Dr. Jim has served on the board of directors of several beef industry groups including the Alberta Cattle Feeders’ Association, Canadian Cattlemen’s Association, Livestock Identification Services Ltd, Canadian Cattle Identification Agency, Canada Beef Export Federation and the Alberta Livestock and Meat Agency. He has also served as Board Chair of the Canada Beef Export Federation and Vice Chairman of the Alberta Cattle Feeder’s Association.

Board and Management

27

Dennis received his Bachelor of Science Degree with honors in Economics and Mathematics from the University of Calgary in 1975. Further pursuing his education, he received his Master of Arts Degree in Economics from Carleton University in Ottawa, Ontario in 1976 and finally, his Juris Doctorate from the University of Calgary in 1979. Dennis has completed the Rotman/ Haskayne Directors Education Program and achieved the designation of Institute-Certified Director (ICD.D) from the Institute of Corporate Directors in 2011. Dennis has also successfully completed the Rotman Financial Literacy Program and has received the TEP designation from the Society of Trust and Estate Planners (STEP). In 2014, Dennis was appointed a Queen's Counsel (QC) of Alberta.

Dennis is presently a director and trustee of a significant number of private financial businesses and trusts. In addition to this he is currently, and has previously been, a director of numerous public companies listed on the TSX Venture Exchange and the Toronto Stock Exchange.

Dennis has professional memberships with:

- The Law Society of Alberta- The Canadian Tax Foundation- The Calgary Bar Association- The Canadian Bar Association- The Society of Trust and Estate Practitioners- The Institute of Corporate Directors, Institute-Certified Director, ICD.D

Dennis L. Nerland, QC

Director

Dr. Greg Andrews

Director

Dr. Andrews is an Equine Veterinarian who has practiced in the Calgary area for 35 years. Until recently he was the CEO of Moore Equine Veterinary Centre which is the largest equine practice in Canada. He was past President of the Alberta Veterinary Medical Association, the Western Canadian Association of Equine Practitioners, as well as involvement with the Canadian Veterinary Medical Association and Equine Canada. Greg has served on the advisory boards of the University of Calgary School of Veterinary Medicine and the Western College of Veterinary Medicine in Saskatoon. His business experience includes positioning Moore Equine to purchase several veterinary clinics in Alberta as well as expanding the practice within the Calgary area. Greg currently chairs the Board of Directors of Inova Partners LLP, a successful veterinary software and management company that services large, complex veterinary practices worldwide which is centered out of Alberta and Texas. He also has been on the boards of small public oil and gas companies and presently has business interests in that industry. Greg received the ICD.D designation from the Institute of Corporate Directors after participating in the Directors Education program of the Rotman School of Business. In early 2016 Dr. Andrews accepted a position on the board of directors for CNA Diagnostics Inc.

Board and Management

28

Professor Emeritus of Medical Biochemistry and Molecular Biology, University of Calgary; founding Professor and Head of the Dept. of Medical Biochemistry, Faculty of Medicine at the University of Calgary and Associate Dean Medical Research. Research in developmental genetics, genome organization, gene expression and embryo manipulation resulted in over 250 publications and invitations for presentations to medical sciences, biotechnology and animal production meetings. A consultant to medical technologies, biotechnology, embryo manipulation and livestock management businesses worldwide.

Dr. Church is a Member of the Order of Canada, and was inducted into the Canadian Agriculture Hall of Fame in 1991. He received the Alberta Order of Excellence in 1993, was named Chief Black Eagle of Treaty #7 Tribes in 1990 and was presented with the Queen Elizabeth II Commemorative Medal in 2002 and the Growing Alberta Distinguished Leadership award in 2003. Dr. Church was inducted into the Alberta Agriculture Hall of Fame and, in 2006, was inducted into the Alberta Bioindustry Hall of Fame.

Dr. Church is a Director of AVAC Ltd., Past Chair of the Alberta Science & Research Authority, Past President of the Calgary Exhibition & Stampede and has served as a Director for many companies, including Alta Livestock Transplants, a precursor to Alta Genetics Inc., Connaught Laboratories Ltd., BiostarInc., CV Technologies, Veterinary Infectious Diseases Organization, CIBA-Geigy, Neurospheres Ltd., Monsanto Co., and Vencap Equities Ltd.

Dr. Robert B. Church PhD

Advisor to the Board

Dr. Christoph W. Sensen

Director & CSO

A founding member of CNADx, Dr. Sensen is a University Professor for Computational Biotechnology at the Graz University of Technology in Austria and an Adjunct Professor at the University of Calgary’s Faculty of Medicine, Department of Biochemistry and Molecular Biology. He participated in a number of large-scale Genome Research programs, including two for the development of markers for CWD and BSE, and co-Author on more than 100 peer-reviewed articles and has edited or published six books in the field of Genome Research and Bioinformatics. Dr. Sensen is a reviewer for granting agencies and Journals; and Associate Editor for Genomics & Bioinformatics for Journal Biotechnology.

Previously research officer at National Research Council of Canada’s Institute for Marine Biosciences (NRC-IMB) and as a visiting scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg. He studied Biology in Mainz, Düsseldorf and Cologne and obtained a Dr. rer. nat. degree from the University of Cologne in 1994. From October 1992 to November 1993, worked as Visiting Scientist at EMBL Heidelberg.

Board and Management

29

A founding member of CNADx, Mr. McCartney is Managing Director of Taylor Butterfield & Worth Asset Management Corporation, a management consulting firm that develops scalable strategies for the commercialization of intellectual property. An established track record in corporate development and new venture incubation, Mr. McCartney has over 20 years experience serving as an officer and director of both private and public companies in the biotechnology and high technology industries.

Including his work at CNA Diagnostics Inc., Mr. McCartney is presently a member of the Board of Directors of Skinvisible Inc., a biotechnology corporation developing polymer delivery systems for applications in dermatology and Kintari International Inc., a specialized brand marketing company for dermatology products using the patented Invisicare™ technology. Mr. McCartney was the former Chairman and President of Biolabs Inc., a biotech incubator supporting diagnostics in transmissible spongiform encephalopathies and the early detection and treatments for breast cancer.E. Greg McCartney

Director , Chairman

& CEO

A founding member of CNADx, Mr. Uniacke is founder, President & CEO of Uniacke & Associates Inc., an investment banking and consulting company based in Calgary, Alberta. Founder and President of NextStep Energy Inc., an alternative energy company focused on licensing, designing, building and operating synthetic fuel facilities domestically and internationally. Founding member, VP and Director of NextStep Renewable Energy Inc., a second generation renewable biofuels company.

Over 40 years of international business experience; 25 years in manufacturing, wholesale and retail; 15 yrs. in the investment banking and consulting business structuring projects with financing requirements ranging from $1 to $300 million.

R.J. Tim Uniacke

Director & VP Business

Development

David Gordon

CFO

David L. Gordon, Bcomm, PMP, CFA. is a business and financial professional with +15 years experience in optimizing business performance and deployingcapital into organizations to maximize potential.

David worked in the investment banking industry with a major Canadian financial institution, and has resolved a wide spectrum of operational, business, and financial issues for small to large-cap clients and government organizations.

David has earned the Chartered Financial Analyst (CFA) designation; is a Project Management Professional (PMP); won the silver medal in Operations Management for his Commerce degree; has completed the CPA CFO operational skills course; is well versed in leadership strategy and has published articles on strategy execution.

Company Highlights

Proprietary technology that identifies chronic disease at the earliest stages for livestock, companion animals and humans.

Lead order for a minimum one million bovine tests at $12 USD per test, high gross margins, subject to initial commercialization (Q4/17 ).

Distribution planned through license agreements with well known major industry participants.

Multi-disease testing platform significantly improves food safety for consumers and the profitability for the livestock industry.

High barriers to entry, long term expansion opportunity, seasoned leadership and a comprehensive product portfolio.

Multibillion dollar market opportunity.

30

31

E. Greg McCartney, CEOCONTACT:CNA Diagnostics Inc. T: +1 604.560.1239greg.m@CNADiagnostics.com

R. J. Tim Uniacke, EVP T: +1 403.663.9952tim@CNADiagnostics.com

Dr. Christoph Sensen, CSOT: +43 (664) 60873-4090christoph.sensen@CNADiagnostics.com

David Gordon, CFOT: +1 403.465.0241david@CNADiagnostics.com

CORPORATE LAWYERShea Nerland LLP1400, 350 – 7th Ave. SWCalgary, Alberta, Canada T2P 2X6

IP LAWYERMerchant & Gould PC3200 IDS Center80 South Eighth StreetMinneapolis, MN

CORPORATE ADVISORSBDO Canada LLP620, 903 – 8th Ave. SWCalgary, Alberta, Canada T2P 0P7

STRATEGIC ADVISORSFramework Partners Inc.405, 906 – 12th Ave. SWCalgary, Alberta, Canada T2R 1K7

CNADiagnostics.com

Contacts

610, 1414 – 8th St. SWCalgary, Alberta T2R 1J6

Tel. 403.714.0888